Prostate Cancer / 2020 / Article / Tab 3 / Research Article
Detection of Prostate Cancer Antigen 3 and Prostate Cancer Susceptibility Candidate in Non-DRE Urine Improves Diagnosis of Prostate Cancer in Chinese Population Table 3 Performance of PCA3 and LBXexo in predicting biopsy outcomes.
Any-grade cancer Biopsy positive Biopsy negative Total Performance PCA3 ≥Cutoff point 10 28 38 PPV % 26.32 <Cutoff point 4 15 19 NPV % 78.95 Total 14 43 57 LBXexo score ≥Cutoff point 12 17 29 PPV % 41.38 <Cutoff point 2 26 28 NPV % 92.86 Total 14 43 57 Sensitivity % Specificity % % of predicted negative PCA3 71.4 34.9 33.33 LBXexo 85.7 60.5 50.88 High-grade cancer (GS ≥ 7) Biopsy positive Biopsy negative + low-grade cancer Total Performance PCA3 ≥Cutoff point 7 31 38 PPV % 18.42 <Cutoff point 1 18 19 NPV % 94.74 Total 8 49 57 LBXexo score ≥Cutoff point 8 21 29 PPV % 27.59 <Cutoff point 0 28 28 NPV % 100 Total 8 49 57 Sensitivity % Specificity % % of predicted negative PCA3 87.5 36.7 33.33 LBXexo 100 57.1 49.12
Abbreviations: PPV, positive predictive value; NPV, negative predictive value.